SOURCE: MB Software Corporation

November 01, 2007 09:30 ET

MBSB Announces Evidence Based Medicine Studies on Wound Care Technologies

FORT WORTH, TX--(Marketwire - November 1, 2007) - MB Software Corporation (OTCBB: MBSB) announced today that its wholly owned subsidiary Wound Care Innovations LLC has begun evidence based studies on its Cellerate Products.

"Having Wound Care's products supported by evidence based medicine studies will boost customer confidence in those products and contributes to market success," stated Scott Haire the company's CEO.

The company's Vice President of Corporate Development, Cathy Bradshaw quoted that the most common definition of evidence based medicine is "the conscientious, explicit and judicious use of current best evidence in making decisions about the care of the individual patient. It means integrating individual clinical expertise with the best available external clinical evidence from the systematic research," (Sackett D, 1996).

Ms. Bradshaw further noted, "Our current product, CellerateRX®, is FDA cleared for marketing for all wounds except 3rd degree burns and is effective in all wound phases and states. CellerateRX is peerless in its simplicity of use and application as an advanced therapy. It significantly reduces the costs of wound care therapies and is safe, biocompatible and biodegradable. It is important to note that our product can be used with all other current wound care therapies. We continue to have great results with the product and now we want to expand those results by getting additional studies on all the different types of wounds we deal with."

CellerateRX is available in two forms, a powder and a gel, and both products feature HCPCS codes for reimbursement.

About MB Software Corporation:

MB Software Corporation (OTCBB: MBSB), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at www.CellerateRX.com.

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Compensation Disclaimer: Capital Pros Network CPN has been compensated the equivalent of $50,000 from MBSB.OB. Certain oral statements made by management from time to time and certain statements contained in press releases and periodic reports issued by Capital Pros Network or MBSB.OB (the "Company"), as well as those contained herein, that are not historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934 and, because such statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.

Contact Information